CALGARY, Alberta, March 11, 2026 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce that it has filed its audited annual financial statements (the “financial statements”) and related management’s discussion and analysis and its annual information form (the “AIF”) for the financial year ended December 31, 2025 (collectively, the “Annual Filings”). The AIF contains the reserves data and other oil and gas information as required by National Instrument 51-101 – Standards of Disclosure for Oil and Gas Activities. The financial and reserves information contained in the Annual Filings is consistent with the unaudited financial and reserves information disclosed in the press release issued by Birchcliff on February 11, 2026. The Annual Filings are available electronically on the...

Delivers financial performance above guidance ranges Full year 2025 worldwide net sales totaled $1 billion Full year gross margin expands 390 basis points to 56.1% Full year operating loss of $19 million and operating margin of (1.9)%; adjusted operating income of $12 million and adjusted operating margin of 1.1% Unveils next evolution of turnaround plan and raises long-term financial targetsRICHARDSON, Texas, March 11, 2026 (GLOBE NEWSWIRE) — Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the fourth quarter and fiscal year ended January 3, 2026. “The bold initiatives under the Turnaround Plan we announced one year ago gained traction quickly, enabling us to deliver operating and financial performance above our expectations for 2025,” said Franco Fogliato, CEO. “We focused on our core brands, channels...

ARR increased 31% year-over-year to $811 million Q4 revenue increased 32% year-over-year to $196.3 million Q4 net cash provided by operating activities was $18.1 million, representing 9% of revenueSANTA CLARA, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Netskope, Inc. (NASDAQ:NTSK) a leader in modern security and networking for the cloud and AI era, today announced financial results for the fourth quarter and fiscal year 2026, ended January 31, 2026. “We closed fiscal 2026 on a strong note, delivering record net new ARR in Q4 and achieving our first full year of positive free cash flow,” said Sanjay Beri, CEO of Netskope. “The AI Supercycle is here, demanding a new standard for high-performance security and networking. We believe the next decade will be defined by an intelligent edge. Our Netskope One platform combined with our...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports TN-301’s Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced financial results for the...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. “We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated development plan for PLN-101095,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. “In addition to oncology and...

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), producer and marketer of sorbent mineral products, today announced results for its second quarter and first six- months of fiscal year 2026.  Second Quarter Year to Date(in thousands, except per share amounts) Ended January 31, Ended January 31,  2026 2025 Change 2026 2025 ChangeConsolidated Results            Net Sales $ 117,737 $ 116,914 1 % $ 238,223 $ 244,859 (3)%Income from Operations * $ 15,693 $ 17,482 (10)% $ 32,647 $ 38,672 (16)%Net Income $ 12,569 $ 12,921 (3)% $ 28,025 $ 29,297 (4)%EBITDA † $ 21,735 $ 22,216 (2)% $ 45,376 $ 48,383 (6)%Diluted EPS – Common $ 0.87 $ 0.89 (2)% $ 1.93 $ 2.01 (4)%Business to Business            Net Sales $ 41,977 $ 43,416 (3)% $ 86,263 $ 91,831 (6)%Segment Operating...

– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m. PT – GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights:NXT-41x Development Program On Track: Elutia continues to advance development of NXT-41x, a next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgery. The Company has submitted the 510(k) application for the base biologic matrix, NXT-41, to FDA and anticipates...

     Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. “Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis® Manufacturing Platform to customers in the RNAi industry. We’ve secured multiple contracts with leading pharma, high growth biotech, and top tier...

B2B infrastructure continues to scale with record full year 2025 revenue of $121.6 million and full year swap volume up 21% to $6.89 billion OMAHA, Neb., March 11, 2026 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or the “Company”), the leading self-custodial cryptocurrency platform and first U.S. publicly traded company to tokenize its stock, today announced its results for the fourth quarter and full year ended December 31, 2025. The Company reported record full year revenue of $121.6 million for fiscal year 2025, an increase of 5% compared to fiscal year 2024, while full year swap volume grew 21% to $6.89 billion.Fourth Quarter and Full Year 2025 Financial Highlights (In USD millions, except percentages) Q4 2025   Q4 2024   % Change     2025     2024   % Change                       Revenue $29.5   $44.8   (34)%   $121.6   $116.3   5%                       Technology,...

CALGARY, Alberta, March 11, 2026 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces fourth quarter and year-end results for the period ended December 31, 2025. 2025 HighlightsCompleted the previously announced termination of the long-standing management agreement with Rife Management Ltd. (formerly Rife Resources Management Ltd.). Achieved record annual production of 16,294 boe/d, a 9% increase from 2024; Total annual crude oil and natural gas liquids production of 10,730 boe/d(1), a 12% increase from 2024; Generated total revenue of $313 million; Bonus and leasing revenue contributed $8 million, an increase from $3 million in 2024; Delivered $235 million in funds from operations ($1.43/share),(2)(4) a 2% increase from 2024; Returned $177 million ($1.08/share)(3) to shareholders through monthly...